TTP054
/ vTv Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 13, 2012
A study to evaluate safety and efficacy of TTP054 for 12 weeks in subjects with type 2 diabetes
(clinicaltrials.gov)
- P2, N=175; Not yet recruiting; New P2 trial
New P2 trial • Diabetes
1 to 1
Of
1
Go to page
1